The stock has slumped this year, seesawing on news of how much the government plans to pay insurers that operate Medicare ...

Humana affirmed its outlook for 2026 on Wednesday morning, though the company's shares fell premarket as future star ratings ...

Humana’s CenterWell Pharmacy business and Mark Cuban’s Cost Plus Drugs have tied the knot on a partnership focused on ...

Humana plans major changes to its Medicare Advantage plans in 2027, focusing on profitability over growth, which could affect ...

Margin improvement and MA member retention are doable, as are top-quartile star-rating results in 2028, company says.

Humana (HUM) stock slides despite a Q1 beat as the company reaffirmed its 2026 EPS guidance due to Medicare Star Ratings cuts. Read more here.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Humana Inc.’s first-quarter profit exceeded Wall Street’s estimates though the company maintained its full-year guidance, suggesting it may foresee difficulties later in the year.

Humana reported first quarter net income of nearly $1.2 billion as costs of care for older adults in its Medicare Advantage ...

The insurance provider, which has a large footprint in Texas, hasn't said how many of its customers were affected by the hack.

CenterWell, Humana’s pharmacy branch, is collaborating with Mark Cuban’s Cost Plus Drug Co. for an employer-based program, according to an April 27 news release. CenterWell will use Cost Plus Drugs’ ...

In a report released today, Lisa Gill from J.P. Morgan maintained a Hold rating on Humana, with a price target of $214.00. Gill covers the Healthcare sector, focusing on stocks such as Cigna, Humana, ...